Related references
Note: Only part of the references are listed.Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid chromatography/electro spray ionization tandem mass spectrometry
Naoe Yamane et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
Graham Lappin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Inhibition of OAT3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid
H Tahara et al.
DRUG METABOLISM AND DISPOSITION (2006)
Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans
M Shimizu et al.
DRUG METABOLISM AND DISPOSITION (2005)
P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion
H Tahara et al.
DRUG METABOLISM AND DISPOSITION (2005)
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
M Niemi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
N Yasui-Furukori et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human
T Nozawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Transport characteristics of fexofenadine in the Caco-2 cell model
N Petri et al.
PHARMACEUTICAL RESEARCH (2004)
Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans
M Molimard et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2004)
Current perspectives of C-14-isotope measurement in biomedical accelerator mass spectrometry
G Lappin et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2004)
Positron emission tomography microdosing:: a new concept with application in tracer and early clinical drug development
M Bergström et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
G Lappin et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Fexofenadine transport in Caco-2 cells: Inhibition with verapamil and ritonavir
MD Perloff et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Effect of St John's wort on the pharmacokinetics of fexofenadine
ZQ Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
GK Dresser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography
EO Aboagye et al.
DRUG DISCOVERY TODAY (2001)
The effect of rifampin administration on the disposition of fexofenadine
MA Hamman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Fexofenadine - A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
K Simpson et al.
DRUGS (2000)
Share Paper
